RFA-CA-23-035: Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to small businesses. Applications closed on August 21, 2023.
From the official notice on Grants.gov, last changed April 21, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR42
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$906,627
- Typical project length2 years
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under RFA-CA-23-035 were run by National Cancer Institute (NCI, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-035 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-CA-22-017 | March 21, 2022 | Closed August 22, 2022 | Closed |
Key dates
| Posted | April 21, 2023 |
|---|---|
| Deadline | August 21, 2023 |
| Archived by Grants.gov | September 26, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 4 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.
Funded under RFA-CA-23-035 so far
NIH funded 8 projects under RFA-CA-23-035 in fiscal 2024 to 2026, at 4 institutions. The median yearly award was $906,627.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Development of small molecule therapeutics targeting AR-V7 for prostate cancer | Arma Bio, Inc. | 2026 | $888,779 |
| Development of Deep Mutational Scanning with Duplex Sequencing (DMS-DS) for anti-cancer drug evaluation and administration | Atlas Biologics, LLC | 2026 | $1.0 million |
| Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer | Cosmyc Inc | 2026 | $970,613 |
| Rapid, Single Cell Proteomic Profiling for Biomarker Development in Precision Oncology | Aperture Bio, Inc. | 2025 | $942,272 |
| Development of Deep Mutational Scanning with Duplex Sequencing (DMS-DS) for anti-cancer drug evaluation and administration | Atlas Biologics, LLC | 2024 | $400,000 |
| Development of small molecule therapeutics targeting AR-V7 for prostate cancer | Arma Bio, Inc. | 2024 | $406,489 |
| Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer | Cosmyc Inc | 2024 | $391,403 |
| Rapid, Single Cell Proteomic Profiling for Biomarker Development in Precision Oncology | Aperture Bio, Inc. | 2024 | $339,990 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Who has won Human Genome Research grants before
From fiscal 2021 to 2025, Human Genome Research (93.172) awarded $2.2 billion across 1,255 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 59 | $153 million |
| University of Washington | Washington | 46 | $123 million |
| The Broad Institute, Inc | Massachusetts | 22 | $119 million |
| University of California Santa Cruz | California | 17 | $64.7 million |
| Baylor College of Medicine | Texas | 24 | $62.9 million |
Other programs behind this notice
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-035 still open?
No. It closed on August 21, 2023.
Who can apply for Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)?
Closed August 21, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-CA-23-035?
NIH RePORTER lists 8 projects funded under RFA-CA-23-035 in fiscal 2024 to 2026, at 4 institutions. The most were at Arma Bio, Inc., Atlas Biologics, LLC, Cosmyc Inc.
Who has won Human Genome Research grants before?
The largest recipients over five fiscal years were The Leland Stanford Junior University, University of Washington, The Broad Institute, Inc. The program made 1,255 awards worth $2.2 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)